Women's Health Issues
Volume 16, Issue 5 , Pages 236-242 , September 2006

Annual productivity costs due to cervical cancer mortality in the United States

  • Ralph P. Insinga, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Dr Ralph P. Insinga, Merck & Co., Inc., UG1C-60, P.O. Box 1000, North Wales, PA 19454-1099.

Received 27 September 2005 ,Revised 16 June 2006 ,Accepted 16 June 2006.

References 

  1. Andersen BL, Anderson B, deProsse C. Controlled prospective longitudinal study of women with cancer: II (Psychological outcomes). Journal of Consulting and Clinical Psychology. 1989;57:692–697
  2. Bell FC, Miller ML. Life tables for the United States Social Security area, 1900–2100. Baltimore, MD: Social Security Administration; 2002;
  3. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald ,  Kramer P,  Weed BS editor. D.L. Cancer prevention and control. New York: Marcel-Dekker; 1995;
  4. Bureau of the Census. Statistical abstract of the United States 1946. Washington, D.C: U.S. Government Printing Office; 1946;
  5. Bureau of the Census. Vital statistics of the United States 1946: Part I. Washington, D.C: U.S. Government Printing Office; 1946;
  6. Bureau of the Census. Statistical abstract of the United States 1935–1982. Washington, D.C: U.S. Government Printing Office; 2005;
  7. Bureau of Economic Analysis. Current dollar and “real” gross domestic product, 1929–2005. Washington, D.C: Author; 2006;
  8. Bureau of Labor Statistics and Bureau of the Census. Current population survey. Washington D.C: Author; 2001;
  9. Bureau of Labor Statistics. Comparison of average hourly earnings, not seasonally adjusted, before and after the March 2005 benchmark. 2005;Available: www.bls.gov/ces/#analytical. Accessed July 1, 2005.
  10. Bureau of Labor Statistics. Employment-population ratio, women. Current population survey. 2005;Available: www.bls.gov/cps/#data. Accessed September 23, 2005.
  11. Cates W American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sexually Transmitted Diseases. 1999;26:S2–S7
  12. Census Bureau. Annual estimates of the population by sex and 5-year age groups for the United States: April 1, 2000 to July 1, 2003 (NC-EST2003-01). 2005;Available: www.census.gov. Accessed May 25, 2005.
  13. Census Bureau. Connecticut QuickFacts. 2005;Available: http://quickfacts.census.gov. Accessed May 24, 2005.
  14. Census Bureau. Monthly postcensal resident population, by single year of age, sex, race and Hispanic origin, 1990–1999. Washington, D.C: Author; 2005;
  15. Census Bureau. Quarterly population estimates, 1980–1990. Washington, D.C: Author; 2005;
  16. Census Bureau. Sex by single years of age, 2000. Washington, D.C: Author; 2005;
  17. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: A strategy for the 21st century (Overview of the updated CDC plan). MMWR Recommended Reports. 1998;47:1–14
  18. Centers for Disease Control and Prevention/National Center for Health Statistics. Deaths from each cause, by 5-year age groups, race, and sex: United States, 1994–2000. Hyattsville, MD: National Vital Statistics System, Mortality; 2000;
  19. Centers for Disease Control and Prevention/National Center for Health Statistics. Deaths from each cause, by 5-year age groups, race, and sex: United States, 2000. Hyattsville, MD: National Vital Statistics System, Mortality; 2000;
  20. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspectives on Sexual and Reproductive Health. 2004;36:11–19
  21. Das GR, Guest JF. Annual cost of bipolar disorder to UK society. British Journal of Psychiatry. 2002;180:227–233
  22. Devesa SS, Silverman DT, Young JL, Pollack ES, Brown CC, Horm JW, et al. Cancer incidence and mortality trends among whites in the United States, 1947–84. Journal of the National Cancer Institute. 1987;79:701–770
  23. Eng TR, Butler WT. The hidden epidemic: Confronting sexually transmitted diseases. Washington, D.C: National Academy Press, Institute of Medicine; 1997;
  24. Food and Drug Administration (FDA). FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus: rapid approval marks major advancement in public health. FDA News. 2006;P06-77:(June 8)
  25. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996;
  26. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. New England Journal of Medicine. 1999;340:1881–1887
  27. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet. 2006;367:1247–1255
  28. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making. 2000;20:332–342
  29. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–1122
  30. Insinga RP, Glass AG, Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiology Biomarkers and Prevention. 2004;13:355–360
  31. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus—related disease. American Journal of Obstetrics and Gynecology. 2004;191:114–120
  32. Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, et al. The screening histories of women with invasive cervical cancer, Connecticut. American Journal of Public Health. 1995;85:791–794
  33. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA: A Cancer Journal for Clinicians. 2005;55:10–30
  34. Johansson PO. Is there a meaningful definition of the value of a statistical life?. Journal of Health Economics. 2001;20:131–139
  35. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: An updated rapid and systematic review and economic analysis. Health Technology Assessment. 2004;8:iii, 1–iii, 78.
  36. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral. Journal of the American Medical Association. 2002;288:1749–1757
  37. Laskey PW, Meigs JW, Flannery JT. Uterine cervical carcinoma in Connecticut, 1935–1973: Evidence for 2 classes of invasive disease. Journal of the National Cancer Institute. 1976;57:1037–1043
  38. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. Cervical cancer in women with comprehensive health care access: Attributable factors in the screening process. Journal of the National Cancer Institute. 2005;97:675–683
  39. Max W, Rice DP, Sung HY, Michel M. Valuing human life: Estimating the present value of lifetime earnings, 2000. San Francisco: Center for Tobacco Control Research and Education, 195 Economic Studies and Related Methods, University of California—San Francisco; 2004;
  40. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecologic Oncology. 2003;88:96–103
  41. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, et al. Setting the target for a better cervical screening test: Characteristics of a cost-effective test for cervical neoplasia screening. Obstetrics and Gynecology. 2000;96:645–652
  42. National Center For Health Statistics. Vital statistics of the United States, 1946–1959. Hyattsville, MD: Author; 2005;
  43. National Center For Health Statistics. Vital statistics of the United States, 1946–1993. Hyattsville, MD: Author; 2005;
  44. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. 2005;55:74–108
  45. Percy CL, Horm JW, Young JL, Asire AJ. Uterine cancers of unspecified origin—A reassessment. Public Health Reports. 1983;98:176–180
  46. Rice DP. Cost of illness studies: What is good about them?. Injury Prevention. 2000;6:177–179
  47. Ries L, Eisner M, Kosary C, Hankey BF, Miller B, Mariotto A, et al. SEER cancer statistics review, 1975–2000. Bethesda, MD: National Cancer Institute; 2003;Available: http://seer.cancer.gov/csr/1975_2000/. Accessed June 15, 2005.
  48. Ries L, Eisner M, Kosary C, Hankey BF, Miller B, Mariotto A, et al. SEER cancer statistics review, 1975–2002. Bethesda, MD: National Cancer Institute; 2005;Available: http://seer.cancer.gov/csr/1975_2002/. Accessed June 15, 2005.
  49. Rolnick S, LaFerla JJ, Wehrle D, Trygstad E, Okagaki T. Pap smear screening in a health maintenance organization: 1986–1990. Preventive Medicine. 1996;25:156–161
  50. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283–2289
  51. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–1540
  52. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology. 2005;6:271–278

PII: S1049-3867(06)00063-6

doi: 10.1016/j.whi.2006.06.005

Women's Health Issues
Volume 16, Issue 5 , Pages 236-242 , September 2006

Article Tools

* Image Usage & Resolution